OCT 01, 2022 2:00 PM PDT

Capsule-based Fecal Microbiota Transplant Treats Clostridiodes Difficile Infection

WRITTEN BY: Annie Lennon

Oral treatment of Fecal Microbiota Transplant (FMT) via capsules has similar effects to colonoscopic FMT administration when treating recurrent Clostridiodes difficile infection (rCDI). The corresponding study was published in Clinical Gastroenterology and Hepatology

Each year in the US, around 200,000 people develop CDI, typically following antibiotic use. the condition is typically treated with antibiotics, which further damage intestinal microbiota. Symptoms of the condition range from diarrhea to life-threatening damage to the colon. 

In the current study, researchers investigated the efficacy of two standardized FMT preparations for treating rCDI: capsule-based FMT and colonoscopy FMT. FMT preparations are composed of intestinal microbes that can restore healthy intestinal microbiota and, in doing so, repair damage caused by antibiotics, ultimately providing resistance to CDI. 

For the study, the researchers recruited 269 patients from six sites. They performed 301 FMTs on the patients, two-thirds of which were capsule-based FMT. The rCDI 'cure' rate was assessed at 1 and 2 months, and safety data were collected within the first 72 hours and at one and two months. 

After one month of treatment, 86% of patients no longer had rCDI. The percentage of ‘cured’ patients, however, fell to 81% at two months. The researchers noted no difference in outcome between those who received FMT via capsules of colonoscopy. 

They wrote, however, that patients who were older and receiving hemodialysis were more likely to experience FMT failure after two months. Nevertheless, both preparations were generally safe. Although they reported one serious adverse event from colonoscopy- aspiration pneumonia- they identified no other safety signals.

The researchers concluded that while successful overall, patient selection is key for optimizing FMT success. They also noted that further research should identify patients for whom FMT was not successful, so they may understand why they did not respond to the therapy. 

 

Sources: Clinical Gastroenterology and HepatologyScience Daily

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 23, 2022
Neuroscience
The Neurobiology of Impulsivity in Children
OCT 23, 2022
The Neurobiology of Impulsivity in Children
McGill University researchers have developed a genetically based score to identify young children who are at risk of imp ...
NOV 14, 2022
Neuroscience
fMRI Study Indicates Brain Abnormalities in People with Post-Treatment Lyme Disease
NOV 14, 2022
fMRI Study Indicates Brain Abnormalities in People with Post-Treatment Lyme Disease
Johns Hopkins University College of Medicine researchers collaborated with the Lyme Disease Research Center to understan ...
NOV 14, 2022
Cancer
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
NOV 14, 2022
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
About 20% of breast cancers exhibit elevated levels of a protein known as HER2.  You may have heard the classifier ...
NOV 18, 2022
Cannabis Sciences
Study Finds Commonly Used Substances Increase Risk of Atrial Fibrillation
NOV 18, 2022
Study Finds Commonly Used Substances Increase Risk of Atrial Fibrillation
A study found that commonly used drugs increase the development of a potentially deadly heart-rhythm disorder called atr ...
NOV 23, 2022
Drug Discovery & Development
Evidence of antibiotic resistance genes in 'zombie' microbes of the arctic permafrost
NOV 23, 2022
Evidence of antibiotic resistance genes in 'zombie' microbes of the arctic permafrost
One of the most significant consequences of climate change is the greenhouse gases generated from the microbial decompos ...
DEC 07, 2022
Drug Discovery & Development
"Study May Proceed" for Major Depressive Disorder Drug
DEC 07, 2022
"Study May Proceed" for Major Depressive Disorder Drug
Vistagen is a clinical-stage pharma company developing drugs for central nervous system disorders (CNS disorders) such a ...
Loading Comments...